Upholding of price by Supreme Court

2009. DR. RATNAKAR PANDEY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question No. 1510 given in the Rajya on the 4th May, 1987 and state:

(a) whether it is a fact that the Supreme Court upheld the prices fixed by this Ministry;

(b) if so, what are the prices fixed for each drug and formulation which were challenged and what price for each was being charged; and

(c) what was the sales of each of the formulation based on each drug for which price challenged along with the production of each drug from the date of litigation to the date of decision of Supreme Court?

THE MINISTER OF INDUSTRY fSHRI J. VENGAL RAO): (a) Yes, Sir.

(b) and (c) The required details regarding prices fixed, production etc. are quite voluminous. The time and efforts required for collection of these details will not be commensurate with the results likely to be achieved.

Reference to collector regarding Dipyradi. mol and Rifampicin

2010. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question No. 4602 given in the Rajya Sabha on the 5th September, 1988 and state;

(a) whether it is a fact that his Min istry finalised the amounts in respect to Gentamycin, Dipyradimol and Rifampicin after taking into consideration the repre sentations and after giving hearing to the parties;

(b) if so, what are the reasons for not making reference to Collector for recovery oi amount in the case of Dipyradimol and Rifampicin;

(c) whether there is any set policy or guidelines in this regard; and

(d) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) The amount assessed in respect of Rifampicin, Gentamycin etc. have been disputed by the Companies. Necessary action for recovery of the amounts would be taken as per due process of law.

Price Fixation of Formulations

2011. SHRI M. KADHARSHA: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 4570 given in the Rajya Sabha on the 5th September, 1988 and state:

(a) what are the names, pack size, and strengths of category-I formulations the prices of which have not yet been notified;

(b) whether it is a fact that prices of Rifampicin plus INH plus B6 capsules, Electral, Metakalfin and other similar packs have not been fixed so far;

(c) whether it is also a fact that leader price of Pyrazinamide 750 mg 100 mg and Ethambutol 100 mg have not been fixed so far

(d) what action has been taken to prevent overcharging of prices that has been going on since long; and

(e) whether his Ministry has initiated any action for recovery of the amount as per the provisions available under DPCO, 1987?

THE MINISTER OF INDUSTRY (SHRI J. VENGALRAO); (a) The number of category I formulations being marketed in different pack sizes is quite large. In most of the cases the price has already been fixed under DPCO, 1987.

(b) The required information in respect of Rifampicin plus INH plus B6 capsules is given in reply to Unstarred Question 1993 for 28-11-88. Rest of the details to the extent available will be? collected and laid on the table of the Rajya Sabha.

(c) to (e) The formulations referred to in the question are being marketed by